60 Degrees Pharma says DSMB backs continuing Phase 2 tafenoquine chronic babesiosis fatigue study

60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc.

SXTP

0.00
  • 60 Degrees Pharma said its independent Data Safety Monitoring Board recommended continuing the B-FREE Phase 2 chronic babesiosis study.
  • Recommendation followed a safety review of the first six patients through Day 30.
  • Trial tests tafenoquine using the ARAKODA regimen for severe, persistent fatigue in chronic babesiosis patients, with fatigue resolution at Day 90 as the primary endpoint.
  • Study targets up to 100 patients, with at least 16 expected to have baseline-confirmed Babesia infection using validated molecular tests.
  • Tafenoquine is FDA-approved for malaria prophylaxis as ARAKODA, not approved for babesiosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.